Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1INDIV 1

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 685Breast Neoplasms 584Neoplasms 468Colorectal Neoplasms 298Prostatic Neoplasms 262Neoplasm Metastasis 256Melanoma 241Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 195Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 141Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Head and Neck Neoplasms 112Squamous Cell Carcinoma of Head and Neck 111Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Small Cell Lung Carcinoma 95Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 76Triple Negative Breast Neoplasms 72

Interventions

RC-1291 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Cancer Cachexia × Clear all
NCT00267358 2013-09-02

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

Helsinn Therapeutics (U.S.), Inc

Phase 2 Completed

Cancer Cachexia

NCT00378131 2013-09-02

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

Helsinn Therapeutics (U.S.), Inc

Phase 2 Completed
51 enrolled

Cancer Cachexia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡